An observational study in Poisoning by Paraquat With Undetermined Intent, sponsored by Ai Peng. Completed at 2 sites in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-06-14.
Sponsored by Ai Peng · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Paraquat poisoning is characterized by multiple organ failure and pulmonary fibrosis with respiratory failure. Accumulating evidence suggested that continuous venovenous hemofiltration (CVVH) had a beneficial role in the treatment of multiple organ dysfunction. The investigators hypothesized that CVVH might restore multiple organ function and reduce the high mortality rate of paraquat poisoning. To confirm it, an prospective clinical study would be carried out.
Paraquat (1,1 '-dimethyl-4,4'-bipyridylium dichloride) is widely used as a herbicide. Accidental or intentional ingestion of paraquat is common in many developing countries such as China, Sri Lanka and Korea because of easy access. The high mortality rate of paraquat is due to its high toxicity and the lack of effective treatments. Thus, the paraquat poisoning becomes one of major medical problem in the developing countries.
Paraquat poisoning is also one of major causes of death among young patients with acute poisoning in China. It is characterized by multiple organ failure and pulmonary fibrosis with respiratory failure. A growing body of evidence suggested that continuous venovenous hemofiltration (CVVH) had a great beneficial role in the treatment of multiple organ dysfunctions. We hypothesized that CVVH might reduce the high mortality rate of paraquat poisoning via restoring the multiorgan function, such as acute hepatic lesion, acute kidney injury, acute lung injury and acute pancreatic injury. We expect to enroll 100 patients from our hospital within 1 week after oral intake of paraquat. All patients were divided into Group 1 and Group 2. Group 1 were treated with a standardized therapeutic regimen including stomach lavage, emergency haemoperfusion and drugs. Group 2 were accepted with standardized treatment plus CVVH. The aim of this prospective clinical study was to evaluate the safety and efficacy of CVVH for the treatment of patients with paraquat poisoning. The survival rate, clinical manifestations and clinical parameters between these two groups were compared.
98 studies on the registry are indexed under Poisoning; 16 are open to participants now.
This study's enrollment of 110 is close to the median of 122 across 41 observational studies indexed under Poisoning.
Browse Poisoning studies →Ai Peng is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
In-patients with acute paraquat poisoning
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients recruited in this study should meet the requirements as follows:
Exclusion Criteria:
Patients who had colorless urine PQ tests, who arrived at any hospital more than 24 h after intoxication, who had not orally ingested PQ or any other drug poisonings, who were younger than 14 years or older than 70 years, or who had been included in any previous control trials were excluded.
Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
Procedure: CVVH
The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
Procedure: CVVH · Procedure: Standardized therapy regimens
Ultrafiltration at 35ml/h/Kg
Also known as: continuous renal replacement treatment(CRRT), continuous blood purification(CBP)
Standardized therapy regimens included the followings: 1. Remove all contaminated clothing 2. Gastric lavage 3. Receive activated charcoal as quickly as possible 4. Hemoperfusion with activated charcoal(160g) 5. Immunosuppression with methylprednisolone 6. Antioxidants (glutathione,1.2 gram iv twice a day) 7. Supportive care
Efficacy
CVVH treatment efficacy was assessed by the following measurements: 1. Mortality rate: compared the difference between standardized therapy and CVVH treatment. 2. Number of organs involved in paraquat poisoning such as lung,kidney,liver and heart. 3. Degree of organ injuries 4. CT scan of lung 5. Biomarkers: 1)Oxidative stress: blood superoxide dismutase(SOD),malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT). 2)Proinflammatory factors: interleukins(IL-2,IL-6,IL-8 and IL-10) 3)Kidney function:serum cystatin C and estimated glomerular filtration rate (eGFR) and N-acetyl-β-(D)-glucosaminidase activity (NAG),kidney injury molecule-1 (KIM-1), Neutrophil gelatinase-associated lipocalin(NAGL) and urinary retinol-binding protein(RBP),etc. 4)Heart damage markers: cTnT,MYO,creatine kinase-MB(CK-MB) and brain natriuretic peptide(BNP).
Time frame: at 6 months after paraquat poisoning
Safety of CVVH for the treatment of patients
Safety and tolerability were assessed by the followings. 1. Changes from baseline in systolic blood pressure and mean artery pressure during CVVH treatment procedure. 2. Number of participants with adverse events such as bleeding, respiratory failure,hypotension,shock,thrombosis,pulmonary embolism and death.
Time frame: at 2 weeks after paraquat poisoning
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Oct 2012, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ai Peng